The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites
Robins, L. N. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790210031005 · Cited by 2,550
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Toward a neurobiology of obsessive-compulsive disorder
Graybiel, A. M., & Rauch, S. L. (2000) · Neuron · doi:10.1016/s0896-6273(00)00113-6 · Cited by 864
Neuroimaging and frontal–subcortical circuitry in obsessive–compulsive disorder
Saxena, S., Brody, A. L., Schwartz, J. M., & Baxter, L. R. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297870 · Cited by 831 · cited 2×
“It is well established that the striatum, globus pallidus, orbitofrontal cortex, and other components of the CSTC circuitry are hypermetabolic in OCD.(127) Because cortico-striatal projections are predominantly glutamatergic, excess striatal glutamate in OCD may simply be a byproduct of increased firing of coritco-str…”
BackgroundSanacora, G., Mason, G. F., Rothman, D. L., Behar, K. L., Hyder, F., Petroff, O. A. C., Berman, R. M., Charney, D. S., & Krystal, J. H. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.11.1043 · Cited by 627
Self-citationMcDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
Abramowitz, J. S. (1997) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.65.1.44 · Cited by 490 · cited 1×
“In the last two decades, efficacious pharmacological and psychotherapeutic treatments for OCD have been developed and extensively validated.(3,13,14) Clomipramine, the tricyclic antidepressant that is the most specific inhibitor of serotonin reuptake, was shown to be efficacious in the treatment of obsessive-compulsiv…”
BackgroundModification of expectations in cases with obsessional rituals
Meyer, V. (1966) · Behaviour Research and Therapy · doi:10.1016/0005-7967(66)90023-4 · Cited by 461
Treatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377
A placebo-controlled trial of risperidone in Tourette syndrome
Scahill, L., Leckman, J. F., Schultz, R. T., Katsovich, L., & Peterson, B. S. (2003) · Neurology · doi:10.1212/01.wnl.0000055434.39968.67 · Cited by 362
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314
Bystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220
Arnold, P., Rosenberg, D., Mundo, E., Tharmalingam, S., Kennedy, J., & Richter, M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1847-1 · Cited by 202
Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197
Katoh, R., Asano, T., Ueda, H., Morishita, R., Takeuchi, I. K., Inaguma, Y., & Kato, K. (2002) · The FASEB Journal · doi:10.1096/fj.02-0143fje · Cited by 193 · cited 2×
“In vitro studies suggest that it also modulates release of acetylcholine and dopamine,107 potentiates receptors for GABA and glycine,108,109 and enhances expression of BDNF.110,111 Preliminary studies suggest efficacy of riluzole therapy several neuropsychiatric disorders in which excessive glutamatergic activity has…”
BackgroundCampbell, K. M., de Lecea, L., Severynse, D. M., Caron, M. G., McGrath, M. J., Sparber, S. B., Sun, L.-Y., & Burton, F. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05044.1999 · Cited by 170 · cited 1×
“therapies have demonstrated marked efficacy in the limited studies done to date.(77)”
BackgroundMizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., & Kuno, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02098-5 · Cited by 145
Leckman, J. F., & Riddle, M. A. (2000) · Neuron · doi:10.1016/s0896-6273(00)00114-8 · Cited by 121 · cited 1×
“and potentially overlapping pathological changes in the basal ganglia are implicated in the two disorders.(48,49)”
BackgroundLi, X., May, R. S., Tolbert, L. C., Jackson, W. T., Flournoy, J. M., & Baxter, L. R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0610 · Cited by 110
MOORE, G. J., MACMASTER, F. P., STEWART, C., & ROSENBERG, D. R. (1998) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199806000-00017 · Cited by 85
Pharmacotherapy for obsessive‐compulsive disorder
Dougherty, D. D., Rauch, S. L., & Jenike, M. A. (2004) · Journal of Clinical Psychology · doi:10.1002/jclp.20083 · Cited by 83
Cited by
The orbitofrontal cortex and beyond: From affect to decision-making
Rolls, E. T., & Grabenhorst, F. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.09.001 · Cited by 807
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“Nevertheless, the hope for therapeutic benefit from such agents, especially in the large fraction of patients' refractory to established treatment approaches , drives continued interest (Pittenger et al., 2006; Pittenger et al., 2008a).”
BackgroundSelf-citationGenetics of early-onset obsessive–compulsive disorder
Walitza, S., Wendland, J. R., Gruenblatt, E., Warnke, A., Sontag, T. A., Tucha, O., & Lange, K. W. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-010-0087-7 · Cited by 402
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Metadata
- Authors
- Pittenger, C., Krystal, J. H., & Coric, V.
- Venue
- NeuroRX
- Published
- 2006-01
- Volume
- 3
- Issue
- 1
- Pages
- 69-81
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W2116655758
- Cited by
- 222
- References
- 26
- FWCI
- 23.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.